Documents | Guidance on the use of imatinib for chronic myeloid leukaemia | Guidance | NICE

Documents

A list of downloadable documents created during development.

Background information

Leukaemia (chronic myeloid) - imatinib: review decision-October 2014 information
Leukaemia (chronic myeloid) - imatinib: appendix a-GE decision paper-October 2014 20 October 2014 111.04 KB
TA70 Leukaemia (chronic myeloid) - imatinib: review proposal August 2014 information
TA70 Leukaemia (chronic myeloid) - imatinib: appendix a - provisional matrix of stakeholders 26 August 2014 104.49 KB
TA70 Leukaemia (chronic myeloid) - imatinib: appendix b - proposal paper presented to the Institute's Guidance Executive 26 August 2014 570.54 KB
Review decision: July 2009 information
Review decision - July 2009 appendix 1: proposal comment summary table 16 July 2009 43.38 KB
Review proposal: May 2009 information
Review proposal: May 2009, Appendix A - provisional matrix 14 May 2009 46.93 KB
Review proposal information
Leukaemia (chronic myeloid) - imatinib: review decision information

Final Appraisal Determination: Imatinib for chronic myeloid leukaemia

Final Appraisal Determination: Imatinib for chronic myeloid leukaemia information
Final Appraisal Determination: Imatinib for chronic myeloid leukaemia 28 August 2003 151.47 KB

Appraisal Consultation Document: Imatinib for chronic myeloid leukaemia

Appraisal Consultation Document: Imatinib for chronic myeloid leukaemia information

Scope: Imatinib for Chronic Myeloid Leukaemia (first line therapy)

Scope: Imatinib for Chronic Myeloid Leukaemia (first line therapy) information

Protocol: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase

Protocol: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase 20 November 2002 141.28 KB

Assessment Report: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase

Assessment Report: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase 13 June 2003 1.17 MB